alendronate has been researched along with hydroxyproline in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 13 (65.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ammann, P; Bonjour, JP; Burckhardt, P; Gertz, BJ; Jaquet-Müller, F; Jenzer, A; Portmann, L; Pryor-Tillotson, S; Rizzoli, R; Zysset, E | 1 |
| Gertz, BJ; Kanis, JA; O'Doherty, DP; Sciberras, DG; Survill, TT; Tindale, W | 1 |
| Adami, S; Garavelli, S; Guarrera, G; Lo Cascio, V; Montesanti, F; Rosini, S; Salvagno, G | 1 |
| Ascari, E; Attardo-Parrinello, G; Crema, F; Fiorentini, ML; Merlini, G; Pavesi, F | 1 |
| Kanis, JA; Khan, S; McCloskey, EV; O'Doherty, DP; Vasikaran, S | 1 |
| Dubois, SK; Pak, CY; Roberts, ML; Ruml, LA | 1 |
| Alfano, FS; Basini, G; Campanini, C; Fantuzzi, M; Gatti, C; Girasole, G; Passeri, M; Pedrazzoni, M | 1 |
| Bertoldo, F; Bettica, P; Braga, V; LoCascio, V; Moro, L; Pasini, AF; Stefani, L | 1 |
| Adami, S; Bertoldo, F; Braga, B; Dorizzi, R; Gatti, D; Locascio, V; Mian, M; Rossini, M; Zamberlan, N | 1 |
| Chesnut, CH; Eyre, DR; Genant, HK; Gertz, BJ; Hanson, DA; Harris, ST; Quan, H; Shao, P | 1 |
| Kanis, JA; Khan, S; McCloskey, EV; Vasikaran, SD | 1 |
| Benéton, MN; Coombes, G; Coulton, L; Kanis, JA; Khan, SA; McCloskey, EV; Orgee, J; Rogers, S; Vasikaran, S | 1 |
| Beneton, MN; Coombes, GM; Gertz, BJ; Holland, SD; Kanis, JA; Khan, SA; Kline, WF; Matuszewski, BK; McCloskey, EV; Orgee, J; Porras, AG; Rogers, SR; Sciberras, DG; Vasikaran, S | 1 |
| Alonzo, E; Bellorín-Font, E; Carlini, R; Machado, C; Martinis, R; Paz-Martínez, V; Weisinger, JR | 1 |
| Stearns, ME | 1 |
| Blackwell, PJ; Fairbairn, KJ; Hosking, DJ; Parker, CR | 1 |
| Blümel, JE; Castelo-Branco, C; de la Cuadra, G; Haya, J; Maciver, L; Moreno, M | 1 |
| Akiyama, Y; Hara, K; Kobayashi, M | 1 |
| Franeková, J; Husek, P; Simek, P; Svagera, Z; Vsianský, F | 1 |
| Afsie, S; Al-Nammari, SS; Timothy, T | 1 |
1 review(s) available for alendronate and hydroxyproline
| Article | Year |
|---|---|
A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy.
Topics: Alendronate; Alkaline Phosphatase; Arthropathy, Neurogenic; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Humans; Hydroxyproline; Imidazoles; Immobilization; Insulin-Like Growth Factor I; Pamidronate; Randomized Controlled Trials as Topic; RANK Ligand; Skin Temperature; Zoledronic Acid | 2013 |
9 trial(s) available for alendronate and hydroxyproline
| Article | Year |
|---|---|
Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxyproline; Hypercalcemia; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Parathyroid Hormone | 1992 |
Effects of five daily 1 h infusions of alendronate in Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxyproline; Kidney; Male; Middle Aged; Osteitis Deformans | 1992 |
Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Hydroxyproline; Male; Middle Aged; Pain | 1987 |
The effects of intravenous alendronate in Paget's disease of bone.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Hydroxyproline; Injections, Intravenous; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Osteitis Deformans; Parathyroid Hormone; Phosphates | 1995 |
Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate.
Topics: Adult; Alendronate; Bed Rest; Biomarkers; Bone and Bones; Bone Density; Calcium; Diphosphonates; Double-Blind Method; Humans; Hydroxyproline; Immobilization; Male; Parathyroid Hormone; Phosphorus; Urinary Calculi | 1995 |
Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Topics: Alendronate; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcium; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxyproline; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Reproducibility of Results | 1994 |
Alendronate in the treatment of Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Biopsy; Calcium; Female; Humans; Hydroxyproline; Male; Osteitis Deformans | 1997 |
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Density; Calcium; Female; Half-Life; Humans; Hydroxyproline; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone | 1997 |
Alendronate daily, weekly in conventional tablets and weekly in enteric tablets: preliminary study on the effects in bone turnover markers and incidence of side effects.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Collagen Type I; Drug Administration Schedule; Female; Heartburn; Humans; Hydroxyproline; Incidence; Middle Aged; Nausea; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Severity of Illness Index; Tablets, Enteric-Coated; Treatment Outcome | 2003 |
10 other study(ies) available for alendronate and hydroxyproline
| Article | Year |
|---|---|
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Topics: Alendronate; Alkaline Phosphatase; Clodronic Acid; Diphosphonates; Drug Resistance; Humans; Hydroxyproline; Infusions, Intravenous; Osteitis Deformans | 1986 |
Acute effects of bisphosphonates on new and traditional markers of bone resorption.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Resorption; Clodronic Acid; Collagen; Collagen Type I; Diphosphonates; Female; Humans; Hydroxyproline; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Osteoporosis; Peptides; Time Factors | 1995 |
Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
Topics: Aged; Alendronate; Biomarkers; Bone Resorption; Diphosphonates; Female; Humans; Hydroxylysine; Hydroxyproline; Hyperparathyroidism; Middle Aged; Parathyroidectomy | 1994 |
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Topics: Aged; Alendronate; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hydroxyproline; Hyperparathyroidism; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Parathyroid Hormone; Phosphates; Postmenopause | 1994 |
Sustained response to intravenous alendronate in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Calcium; Female; Humans; Hydroxyproline; Injections, Intraperitoneal; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Parathyroid Hormone | 1995 |
[Role of bones in the physiopathology of idiopathic hypercalciuria: effect of amino-bisphosphonate alendronate].
Topics: Alendronate; Bone and Bones; Bone Density; Bone Resorption; Calcium; Cytokines; Humans; Hydroxyproline; Urinary Calculi | 1997 |
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.
Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Collagen; Gelatinases; Humans; Hydroxyproline; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Prostatic Neoplasms; Transforming Growth Factor beta; Tritium; Tumor Cells, Cultured | 1998 |
Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hyperparathyroidism; Male; Middle Aged; Osteocalcin; Osteoporosis; Parathyroid Hormone; Phosphates; Time Factors | 2002 |
Effects of vitamin K2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet.
Topics: Alendronate; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Calcitriol; Calcium; Elasticity; Femur; Hydroxyproline; Magnesium; Magnesium Deficiency; Male; Osteocalcin; Parathyroid Hormone; Rats; Rats, Wistar; Stress, Mechanical; Urine; Vitamin K 2 | 2004 |
Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Resorption; Dipeptides; Female; Humans; Hydrolysis; Hydroxyproline; Middle Aged; Osteoporosis, Postmenopausal; Time Factors | 2008 |